* & is Dentons' Preferred Law Firm in 北京士成(宜昌)律师事务所 湖北省宜昌市西陵区夷陵大道 72 号 州大厦 A 座 14-16 层 邮编:443000 Beijing Dacheng Law Offices, LLP(Yichang) 14-16 F. Tower A. Jiuzhou Building No 72 Yiling Avenue, Xiling District 443000, Yichang, Hubei, China 北京大成(宜昌)律师事务所 关于湖北华强科技股份有限公司 2024 年年度股东大会的 法 律 意 见 书 大成 is Dentons'Preferred Law Firm in China. 北京大成(宜昌)律师事务所 www.dacheng.com 湖北省宜昌市西陵区夷陵大道 72 号九州大厦 A 座 14-16 层 (443000) 14-16 F, Tower A, Jiuzhou Building No.72, Yiling Avenue, Xiling District ,443000, Yichang, Hubei, Chi ...

| 保荐机构名称：华泰联合证券有限责任公司 | 被保荐公司简称：华强科技 | | --- | --- | | 保荐代表人姓名：刘伟 | 联系电话：021-38966588 | | 保荐代表人姓名：张展培 | 联系电话：010-56839300 | 根据《证券法》《证券发行上市保荐业务管理办法》和《上海证券交易所科 创板股票上市规则》等有关法律、法规的规定，华泰联合证券有限责任公司（以 下简称"华泰联合证券"或"保荐机构"）作为湖北华强科技股份有限公司（以 下简称"华强科技"或"公司"）首次公开发行股票并在科创板上市项目的保荐 机构，对华强科技进行持续督导，并出具本持续督导跟踪报告。 华泰联合证券有限责任公司 关于湖北华强科技股份有限公司 2024 年度持续督导跟踪报告 一、保荐机构和保荐代表人发现的问题及整改情况 （一）募集资金投资项目进展不及预期 截至2024年末，公司募投项目新型核生化应急救援防护装备产业化生产基地 项目（以下简称"生产基地项目"）、新型核生化防护基础材料研发平台建设项 目（以下简称"研发平台项目"）和信息化（数据驱动的智能企业）建设项目（以 下简称"信息化项目"）的募集资金累计投入进度分 ...

关于湖北华强科技股份有限公司 首次公开发行股票并在科创板上市 之保荐总结报告书 | 保荐机构名称 | 华泰联合证券有限责任公司 | | --- | --- | | 保荐机构编号 | Z26774000 | 一、保荐机构及保荐代表人承诺 保荐总结报告书 华泰联合证券有限责任公司 1、保荐总结报告书和证明文件及其相关资料的内容不存在虚假记载、误导 性陈述或重大遗漏，保荐机构及保荐代表人对其真实性、准确性、完整性承担法 律责任。 2、本机构及本人自愿接受中国证券监督管理委员会（以下简称"中国证监 会"）、上海证券交易所对保荐总结报告书相关事项进行的任何质询和调查。 3、本机构及本人自愿接受中国证监会按照《证券发行上市保荐业务管理办 法》的有关规定采取的监管措施。 二、保荐机构基本情况 | 情况 | 内容 | | --- | --- | | 保荐机构名称 | 华泰联合证券有限责任公司 | | 注册地址 | 深圳市前海深港合作区南山街道桂湾五路 128 号前海深港基金小 | | | 镇 栋 B7 401 | | 主要办公地址 | 北京市西城区丰盛胡同 22 号丰铭国际大厦 A 座 6 层 | | 法定代表人 | 江禹 ...

Group 1 - The core viewpoint of the news is that the military equipment restructuring concept has seen a significant increase of 5.31%, leading the concept sector in terms of growth [1][2] - Within the military equipment restructuring concept sector, seven stocks experienced gains, with Hunan Tianyan and Construction Industry hitting the daily limit, while Changcheng Military Industry, Dong'an Power, and Huachuang Technology also showed notable increases of 6.23%, 5.46%, and 4.49% respectively [1][2] Group 2 - The military equipment restructuring concept sector attracted a net inflow of 423 million yuan from main funds today, with six stocks receiving net inflows [2][3] - The stock with the highest net inflow was Construction Industry, which saw a net inflow of 261 million yuan, followed by Hunan Tianyan, Changcheng Military Industry, and Dong'an Power with net inflows of 81.57 million yuan, 53.78 million yuan, and 16.46 million yuan respectively [2][3] - In terms of fund inflow ratios, Construction Industry, Hunan Tianyan, and Huachuang Technology had the highest net inflow rates of 19.42%, 18.58%, and 9.71% respectively [3]

Core Viewpoint - The pharmaceutical packaging industry in China is experiencing steady growth, with the market size expected to reach 143.96 billion yuan in 2024, driven by the expansion of the domestic pharmaceutical market and increasing demand for medicines due to aging population and improved healthcare systems [1][11]. Industry Definition and Classification - Pharmaceutical packaging refers to a range of materials and containers used to protect medicines, facilitate storage and transportation, promote sales, provide drug information, and ensure medication safety [2]. Industry Chain Analysis - The pharmaceutical packaging industry chain includes multiple sectors: raw material supply, packaging material manufacturing, drug packaging and application, and auxiliary services. The upstream involves the supply of materials like plastics, glass, metals, and paper, which are crucial for the manufacturing of packaging materials [3]. Industry Development History - The development of the pharmaceutical packaging industry in China has gone through three stages: initial development, rapid expansion, and transformation and innovation. The industry has evolved from relying on imports to adopting advanced technologies and focusing on brand building and market expansion [6]. Current Industry Status - China is the world's largest producer of plastic products, with a production volume of 77.08 million tons in 2024. The availability and pricing of plastic products directly impact the pharmaceutical packaging industry [9][11]. Market Structure - The market structure of the pharmaceutical packaging industry is diverse, with plastic packaging holding a 48% share, followed by glass packaging at 28%, metal packaging at 11%, and rubber packaging at 7% [12]. Key Enterprises Analysis - The competitive landscape of the pharmaceutical packaging industry is diverse and intense. Key players include Shandong Pharmaceutical Glass, Zhengchuan Co., Hualan Co., Haishun New Materials, and Huqiang Technology, each with unique strengths and market positions [15][18][20]. Future Development Trends - The industry is moving towards high-end and high-performance packaging materials, focusing on new technologies and innovative designs to meet the demands of high-end pharmaceuticals [22]. - Green and environmentally friendly packaging is becoming a significant trend, with companies seeking biodegradable and recyclable materials to reduce environmental impact [23]. - The industry is also undergoing consolidation and internationalization, with companies optimizing resources and expanding into international markets to enhance competitiveness [24].

2024 年年度股东大会会议资料 证券代码：688151 证券简称：华强科技 湖北华强科技股份有限公司 2024 年年度股东大会 会议资料 二〇二五年五月 | 湖北华强科技股份有限公司 | 年年度股东大会会议须知 2024 | 1 | | --- | --- | --- | | 湖北华强科技股份有限公司 | 2024 年年度股东大会会议议程 | 4 | | 报告一： | | 7 | | 2024 | 年度独立董事述职报告（王广昌） | 7 | | 2024 | 年度独立董事述职报告（刘洪川） | 16 | | 2024 | 年度独立董事述职报告（刘景伟） | 25 | | 议案一 | ：2024 年度董事会工作报告 | 34 | | 议案二 | ：2024 年度监事会工作报告 | 50 | | 议案三 | ：2024 年年度报告全文及其摘要 | 55 | | 议案四 | ：2024 年度财务决算报告 | 56 | | 议案五 | ：2025 年度财务预算报告 | 63 | | 议案六 | ：2024 年度利润分配方案 | 65 | | 议案七 | ：关于预计 2025 年度日常关联交易的议案 | 67 | | ...

Group 1 - The core viewpoint of the news is that the military equipment restructuring concept has seen a significant increase, with a rise of 3.43%, ranking sixth among concept sectors [1][2] - Within the military equipment restructuring sector, seven stocks experienced gains, with Zhongguangxue hitting the daily limit, and other notable performers including Jianshe Industrial, Dong'an Power, and Hunan Tianyan, which rose by 5.39%, 2.54%, and 2.51% respectively [1][2] Group 2 - The military equipment restructuring sector attracted a net inflow of 152 million yuan from main funds today, with five stocks receiving net inflows [2][3] - Zhongguangxue led the net inflow with 63.15 million yuan, followed by Jianshe Industrial, Chang'an Automobile, and Changcheng Military Industry, which saw net inflows of 45.55 million yuan, 32.11 million yuan, and 11.35 million yuan respectively [2][3] - In terms of fund inflow ratios, Zhongguangxue, Jianshe Industrial, and Changcheng Military Industry had the highest net inflow rates at 28.81%, 7.91%, and 7.22% respectively [3]

华泰联合证券有限责任公司 关于湖北华强科技股份有限公司 2024 年度现场检查报告 根据中国证监会《证券发行上市保荐业务管理办法》和《上海证券交易所上 市公司自律监管指引第 11 号——持续督导》等有关法律法规的要求，华泰联合 证券有限责任公司（以下简称"华泰联合证券"或"保荐机构"）作为湖北华强 科技股份有限公司（以下简称"华强科技"或"公司"）首次公开发行股票并在 科创板上市的保荐机构，于 2025 年 4 月 18 日至 2025 年 4 月 19 日对公司 2024 年度有关情况进行了现场检查。现将本次现场检查情况报告如下： 一、本次现场检查的基本情况 华泰联合证券针对华强科技实际情况制订了 2024 年度现场检查工作计划。 为顺利实施本次现场工作，提高现场工作效率，切实履行持续督导工作，华泰联 合证券于 2025 年 4 月 18 日以书面形式将现场检查事宜通知湖北华强科技股份有 限公司，并要求公司提前准备现场检查工作所需的相关文件和资料。 2025 年 4 月 18 日至 19 日，华泰联合证券现场检查人员根据事先制订的现 场检查工作计划，采取与公司高级管理人员进行沟通和询问、查看公司生产经营 场 ...

尽管营业收入和净利润出现下滑，但公司的每股经营性现金流为0.09元，同比增长了136.29%，显示出 公司在现金流管理上有所改善。货币资金为10.6亿元，较去年同期增长了11.17%，表明公司现金资产较 为健康。然而，应收账款为5.29亿元，较去年同期减少了16.63%，应收账款周转情况值得关注。 商业模式与融资分红 近期华强科技(688151)发布2025年一季报，证券之星财报模型分析如下： 华强科技2025年一季度财务表现 经营业绩 华强科技(688151)在2025年一季度的营业总收入为6498.23万元，较去年同期下降了46.45%。归母净利润 为188.31万元，同比大幅下降86.69%。扣非净利润为-1056.55万元，同比下降40.29%。这表明公司在主 营业务上的盈利能力出现了明显的下滑。 利润率与成本控制 公司的毛利率为16.56%，较去年同期减少了22.33个百分点；净利率为2.9%，同比减少了75.14个百分 点。三费(销售费用、管理费用、财务费用)总计1866.67万元，占营收比例达到28.73%，同比增加了 49.75%。这说明公司在成本控制方面面临较大压力，尤其是三费占比的上升。 ...

Group 1 - Yilida plans to repurchase shares worth 30 to 50 million yuan for employee stock ownership plans, with a maximum price of 6.5 yuan per share [1] - Yinglian shares two major shareholders plan to reduce their holdings by up to 5% [1][2] - Zhongbing Hongjian reports a net loss of 327 million yuan for 2024, with a revenue decline of 25.29% [2][3] Group 2 - Zhongke Electric reports a net profit increase of 626.56% for 2024, with a revenue growth of 13.72% [3][4] - Yong'an Futures reports a net profit decline of 21.07% for 2024, with a revenue decrease of 8.76% [5][6] - Yongjie New Materials reports a net profit increase of 34.28% for 2024, with a revenue growth of 24.71% [7][8] Group 3 - Xibu Securities reports a net profit increase of 20.38% for 2024, despite a revenue decline of 2.64% [9][10] - Jinying Heavy Industry reports a net profit decline of 35.54% for 2024, with a slight revenue increase of 1.13% [10][11] - Haineng Industry reports a net profit decline of 40.45% for 2024, despite a revenue growth of 16.26% [12][13] Group 4 - Penghui Energy reports a net loss of 252 million yuan for 2024, with a revenue increase of 14.83% [14][15] - Weiming Pharmaceutical reports a net loss of 137 million yuan for 2024, with a revenue decline of 16.14% [16][17] - Huachang Technology reports a net profit increase of 184.26% for 2024, with a revenue growth of 6.74% [18][19] Group 5 - Ancar Detection reports a net loss of 213 million yuan for 2024, with a revenue decline of 3.05% [20][21] - Saiwei Intelligent reports a net loss of 507 million yuan for 2024, with a significant revenue decline of 68.03% [22][23] - Qinglong Pipe Industry reports a net profit increase of 976.43% for 2024, with a revenue growth of 36.71% [24][25] Group 6 - Huayin Electric reports a net loss of 113 million yuan for 2024, with a revenue decline of 16.00% [26][27] - Zhongqi New Materials reports a net profit decline of 61.59% for 2024, with a revenue decrease of 22.88% [28][29] - Guangzheng Eye Hospital reports a net loss of 175 million yuan for 2024, with a revenue decline of 16.94% [30][31] Group 7 - Zhenlan Instrument reports a net profit increase of 2.16% for 2024, with a revenue growth of 11.63% [32][33] - Zaiseng Technology reports a net profit increase of 137.99% for 2024, despite a revenue decline of 10.87% [34][35] - Haitai High-tech reports a net profit increase of 51.34% for 2024, with a revenue growth of 25.26% [36][37] Group 8 - Runze Technology reports a net profit increase of 1.62% for 2024, with a revenue growth of 0.32% [38][39]